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Dangers of Treatment
Erythropoietin (Epo)-stimulating 
agents are often used to manage 
cancer therapy–induced anemia 
and improve patients’ quality 
of life. In the face of conflicting 
results concerning the safety 
and efficacy of these treatments, 
Mirmohammadsadegh and 
colleagues reported increased 
Epo receptor expression in 
a majority of the melanoma 
metastases sampled. In 
addition, Epo treatment evoked 
antiapoptotic and promigratory 
effects on these cells in culture. 
Thus, Epo-stimulating therapy 
probably promotes tumor 
growth and metastases in 
melanomas with intact Epo 
receptor signaling, indicating 
that this treatment may not 
be beneficial for patients with 





model” for melanoma asserts 
that host susceptibility and 
chronic sun exposure are both 
causes of melanoma. Hacker 
and colleagues examined the 
relationship between germline 
mutations in the melanocortin-1 
receptor gene (MC1R) and 
somatic mutations in the BRAF 
gene in Australian melanoma 
patients. In support of this model, 
melanomas harboring BRAF V600 
mutations were more frequent 
among younger patients, those 
with high nevus counts, and those 
without high levels of lifetime sun 
exposure. In addition, despite 
recent reports to the contrary, no 
association between germline 
MC1R status and somatic BRAF 
mutations was observed.  
See page 241
Gone Fishing
Transgenic animal models are essen-
tial for elucidating the effects elicited 
by a tumor-inducing gene. Schartl and 
colleagues developed a transgenic 
melanoma model by transferring xmrk-
dependent melanoma development 
from Xiphophorus to the medaka. Xmrk 
causes malignant tumors in Xiphophorus fish, and, indeed, the transgenic medaka 
developed malignant melanoma with 100% penetrance. The melanomas were ultra-
structurally and histopathologically similar to those found in humans. This stable trans-
genic melanoma model will facilitate future studies on the genetic and biochemical 
requirements for this cancer type and provide a tool for large-scale chemical com-
pound library testing and identification of tumor modifier genes. See page 249
Different Paths to the Same Result
Although the melanocyte-specific 
monobenzyl ether of hydroquinone 
(MBEH) is the only approved treat-
ment for depigmentation therapy in 
vitiligo patients in the United States, 
4-tertiary butyl phenol (4-TBP) is also 
specifically cytotoxic to melanocytes. 
Hariharan and colleagues demonstrat-
ed that MBEH treatment results in the 
induction of necrotic cell death in mel-
anocytes, in contrast to the induction 
of apoptosis by 4-TBP treatment. These 
data suggest that MBEH is more likely 
than 4-TBP to invoke an inflammatory 
response that may induce autoreactivity to melanosomal antigens and subsequent 
distant depigmentation. In addition, melanin functions as a protective agent against 
MBEH-induced cell death, suggesting that darker-skinned individuals may not reap 
the full benefits of this treatment. See page 211
Mysterious Medulla
As a continuation of their studies of dif-
ferential keratin expression in the various 
compartments of the human hair follicle, 
Langbein and colleagues performed a sys-
tematic immunohistochemical analysis of 
the keratins in the medulla of human beard 
hairs using antibodies against 52 of the 54 
known human keratins. Interestingly, the 
number of keratins expressed in this central 
hair cortex compartment was higher than 
that in cells of other hair follicle compart-
ments. These promiscuous medulla keratins 
comprise 12 hair keratins and 12 epithelial keratins, including both classical and hair 
follicle–specific epithelial keratins. See page 55
Journal of Investigative Dermatology (2010) 130, 3. doi:10.1038/jid.2009.375
